Sigaud R, Rosch L, Gatzweiler C, Benzel J, et al. The first-in-class ERK inhibitor ulixertinib shows promising activity in MAPK-driven pediatric low-grade glioma models. Neuro Oncol 2022 Jul 27. pii: 6650335. doi: 10.1093.
PMID: 35882450